Oncolys BioPharma, Inc. (4588) AI Stock Analysis

• Market Cap: ¥15.30B
• Dividend Yield: N/A
• Average Volume (3M): 428.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: 11.93%
• EPS Growth: 15.04%
• Country: JP
• Employees: 40
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -32.66
• Shares Outstanding: 24,961,600
• 10 Day Avg. Volume: 324,680
• 30 Day Avg. Volume: 428,420
• PEG Ratio: 0.39
• Price to Book (P/B): 7.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥584.00
• Price Target Upside: -5.65% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: ¥613.00 ▼(-0.97%Downside)

Oncolys BioPharma, Inc.'s stock score is primarily impacted by its weak financial performance, with persistent losses and negative cash flows posing significant risks. The technical analysis indicates some short-term bullish potential, but this is overshadowed by poor valuation metrics, including a negative P/E ratio. Investors should be cautious given the company's current financial instability.

Oncolys BioPharma, Inc. Business Overview & Revenue Model

Company Description

Oncolys BioPharma, Inc. (4588) is a biotechnology company specializing in the development of innovative cancer treatments and diagnostic solutions. The company focuses on the research and development of novel therapeutics, particularly oncolytic viral therapies and other cancer-targeting agents. Its core product pipeline includes Telomelysin (OBP-301), an oncolytic virus therapy designed to selectively target and destroy cancer cells, and OBP-601, a reverse transcriptase inhibitor for viral infections.

How the Company Makes Money

Oncolys BioPharma, Inc. generates revenue primarily through research and development collaborations, licensing agreements, and potential milestone payments related to its drug candidates. The company engages in strategic partnerships with larger pharmaceutical firms to jointly develop and commercialize its therapeutic products, which can provide upfront payments, research funding, and potential royalties on sales. Additionally, Oncolys may earn income from government grants and subsidies aimed at supporting innovative biopharmaceutical research. Although the company is still in the development stage, its long-term revenue growth relies on successfully bringing its drug candidates to market, thereby initiating product sales and generating licensing income.

Oncolys BioPharma, Inc. Financial Statement Overview

Summary

Oncolys BioPharma, Inc. faces significant financial challenges with declining revenues, persistent losses, and negative cash flows, indicating risks to long-term viability. Despite a strong equity position, the inability to achieve profitability is concerning.

Income Statement

Oncolys BioPharma, Inc. has experienced significant revenue decline, with a drop from 2022 to 2023 and further to 2024. The company has consistently operated at a loss, with negative EBIT and net income margins, reflecting challenges in scaling profitable operations.

Balance Sheet

The company maintains a healthy equity position with a strong equity ratio, indicative of solid capitalization. However, the continued losses affect return on equity negatively. While debt levels are manageable, the lack of profitability is concerning for long-term stability.

Cash Flow

Operating and free cash flow have remained negative, indicating ongoing operational cash burn. Despite positive financing cash flow, likely from fundraising, the inability to generate positive cash flow from operations is a critical risk.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	31.38M	63.04M	976.18M	642.49M	314.18M
Gross Profit	31.38M	30.61M	338.49M	198.80M	236.11M
EBITDA	-1.68B	-1.93B	-1.14B	-1.60B	-2.08B
Net Income	-1.68B	-1.94B	-1.15B	-1.62B	-2.10B
Balance Sheet
Total Assets	3.20B	2.04B	2.65B	4.29B	2.80B
Cash, Cash Equivalents and Short-Term Investments	2.41B	1.53B	1.71B	3.45B	2.07B
Total Debt	324.64M	315.17M	393.66M	503.47M	525.08M
Total Liabilities	446.65M	566.50M	491.69M	697.88M	793.09M
Stockholders Equity	2.75B	1.47B	2.16B	3.59B	2.00B
Cash Flow
Free Cash Flow	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Operating Cash Flow	-2.02B	-1.34B	-1.72B	-1.74B	-1.47B
Investing Cash Flow	-4.71M	-5.39M	20.12M	-942.00K	-37.58M
Financing Cash Flow	2.88B	1.14B	-113.83M	3.09B	242.26M

Oncolys BioPharma, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 619.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4588, the sentiment is Positive. The current price of 619 is below the 20-day moving average (MA) of 619.50, above the 50-day MA of 606.04, and above the 200-day MA of 612.06, indicating a neutral trend. The MACD of 1.19 indicates Positive momentum. The RSI at 48.89 is Neutral, neither overbought nor oversold. The STOCH value of 24.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4588.

Oncolys BioPharma, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4880	69 Neutral	¥14.23B	284.55		0.70%	-13.57%	-106.11%
Sector *	60 Neutral	HK$17.07B	6.10	-7.44%	2.88%	11.55%	-28.15%
4579	55 Neutral	¥13.08B	―		―	57.13%	-66.39%
4888	55 Neutral	¥14.06B	―		―	256.62%	81.71%
4583	48 Neutral	¥10.00B	―		―	14.41%	27.42%
4588	48 Neutral	¥15.30B	―		―	11.93%	15.04%
4599	47 Neutral	¥19.32B	―		―	-100.00%	-1079.89%

Oncolys BioPharma, Inc. Corporate Events

Oncolys BioPharma Reports Decline in Q1 2025 Financial Results

Oncolys BioPharma Inc. reported its financial results for the first quarter of 2025, showing a significant decline in net sales and profits compared to the previous year. The company’s financial position weakened, with total assets and equity ratio decreasing, reflecting challenges in maintaining profitability and market stability.